Tesamorelin Side Effects

Reported Tesamorelin side effects

Tesamorelin has a well-characterized side-effect profile from the FDA approval program, which is a significant advantage over non-approved GHRH analogs. Common (>10% in Phase 3 trials) Injection site reactions — erythema, pruritus, pain at site; most frequent adverse event (~22% of patients); usually mild and resolves with site rotation Arthralgia (joint aches) — IGF-1-mediated connective tissue effect; typically appears 4-8 weeks into dosing and stabilizes Pain in extremities — related to fluid shifts and peripheral tissue expansion Myalgia — mild muscle aches, also from IGF-1-mediated connective tissue changes Peripheral edema — dose-dependent GH-mediated fluid retention; mild and usually resolves within weeks Uncommon (1-10%) Carpal tunnel symptoms — fluid-shift-mediated peripheral compression; should prompt dose reduction or discontinuation Paresthesias (hand tingling) — early sign of fluid retention Insulin resistance / raised fasting glucose: all GH-raising therapies impair glucose tolerance; the FDA label reports an intent-to-treat odds ratio of 3.3 (CI 1.4, 9.6) for reaching HbA1c of 6.5% or more Rash / urticaria — hypersensitivity-spectrum reactions Important Hyperglycemia / new-onset diabetes: 5% of treated patients reached HbA1c of 6.5% or more by week 26 versus 1% on placebo; patients with diabetes or pre-diabetes need close monitoring Fluid retention with CHF — contraindicated in patients with acute critical illness, heart failure, or severe edema IGF-1 rise above the reference range: per the FDA label, 47% of patients had IGF-1 above 2 SDS and 36% above 3 SDS at 26 weeks, and 34% and 23% at 52 weeks Black box / boxed warnings — Tesamorelin has no FDA boxed warning. Contraindications per FDA label Disruption of the hypothalamic-pituitary axis (pituitary tumor removal, hypopituitarism, hypothalamic injury) Active malignancy — absolute; GH/IGF-1 axis may accelerate tumor growth Pregnancy — contraindicated Pediatrics — not studied What tesamorelin DOES NOT do Does NOT elevate prolactin or cortisol (unlike GHRP-2/6 / hexarelin) Does NOT cause the continuous GH elevation of CJC-1295-DAC Does NOT cause the acromegalic-body-composition changes of chronic recombinant GH (because the pulse pattern preserves physiologic regulation) Does NOT cause injection-site lipodystrophy seen with some older peptide injections Monitoring requirements Per FDA label and standard clinical practice: Baseline: IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel, thyroid (TSH, free T4) Weeks 4-8: IGF-1 — target within age-adjusted reference range; dose-reduce or discontinue if ULN exceeded Quarterly (on long-term therapy): HbA1c, fasting glucose, liver function, IGF-1 Annually: Reassess need for continued therapy (it is suppressive, not curative) Long-term safety framing The Phase 3 + extension data covers ~2 years; beyond that, safety is extrapolated from the broader GH/IGF-1 literature. Active surveillance for malignancy (general cancer screening appropriate for age and sex), periodic IGF-1 monitoring, and glucose/HbA1c surveillance are the standard clinical practices for adults on tesamorelin beyond 2 years.

When to continue, reduce, or stop Tesamorelin

Tesamorelin contraindications

Absolute contraindications (per FDA label) Disruption of the hypothalamic-pituitary axis — pituitary tumor or removal, hypopituitarism, hypothalamic injury. Tesamorelin requires an intact pituitary to work and can potentially accelerate residual tumor growth Active malignancy — GH/IGF-1 axis may accelerate tumor growth. Absolute contraindication during active cancer treatment or within 5 years of complete remission Pregnancy — category X; do not use Active proliferative or severe non-proliferative diabetic retinopathy — GH elevation can worsen retinopathy Known hypersensitivity to tesamorelin or mannitol (excipient in commercial formulation) Additional off-label biohacking contraindications Uncontrolled T2DM — tesamorelin acutely impairs glucose tolerance; should be optimized before starting Active diabetic retinopathy (any grade) — even non-proliferative History of acromegaly or pituitary adenoma — absolute Severe heart failure (NYHA III-IV) — fluid retention can precipitate decompensation Acute critical illness — tesamorelin is not safe during severe acute illness (sepsis, post-surgical critical care); this mirrors recombinant GH warnings Relative contraindications (consult physician before use) Type 2 diabetes or pre-diabetes — use with monitoring; expect HbA1c elevation of ~0.1-0.3 points Uncontrolled hypertension — fluid retention can exacerbate blood pressure History of carpal tunnel syndrome — fluid retention can reactivate symptoms Hypothyroidism — thyroid status affects GH axis; optimize thyroid first Age >70 — limited efficacy data; safety data from HIV trials does not include most elderly populations Drug interactions Glucocorticoids (chronic systemic) — suppress GH axis and blunt tesamorelin efficacy Insulin and oral hypoglycemics — tesamorelin's effect on glucose tolerance may require dose adjustments CYP3A4 substrates — tesamorelin is not a CYP3A4 inhibitor or inducer; minimal interactions Exogenous recombinant GH — do not combine; redundant Other GHRH analogs — do not use simultaneously at the same receptor Monitoring requirements Baseline: IGF-1, fasting glucose, HbA1c, complete metabolic panel, thyroid (TSH, free T4), PSA (men >40), CBC, lipid panel Week 4-6: IGF-1 (target: within age-adjusted reference range, typically <250 ng/mL for adults 30-50) Every 12 weeks on therapy: IGF-1, HbA1c, fasting glucose Annually: Full panel + reassess need for continued therapy Discontinuation criteria Stop tesamorelin and consult a clinician if you develop: IGF-1 > age-adjusted upper limit HbA1c rising >0.4 points within one cycle Persistent peripheral edema or new carpal tunnel symptoms Any new palpable mass, changing mole, or unexplained weight loss (cancer workup indicated) Severe headache, visual changes (rule out pituitary pathology) Signs of fluid overload or CHF decompensation

Why vendor quality drives Tesamorelin side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Tesamorelin side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .